October 21st, 2011, by David Pascoe | finacea, patents
An unusual patent has surfaced that is suggesting the oral use of azelaic acid. Azelaic Acid is better known as the active ingredient in the topical finacea. This patent suggests an oral treatment that combines niacinamide with azelaic acid. The owner of the patent, Elorac is known from their recent trials of Carbamide Peroxide as a rosacea treatment. Finacea has received some …
September 8th, 2011, by David Pascoe | oracea, patents
An interesting note from the detailed interim judgement in the ongoing patent dispute between Galderma and Mylan. As part of the proceedings Mylan looked at the on-going Oracea sales and projected that Galderma can expect to receive around $260 million in 2011. MYLAN PHARMACEUTICALS INC., v. GALDERMA LABORATORIES, L.P.; et. al. …
August 30th, 2011, by David Pascoe | oracea, patents
Another step in the ongoing battle between Galderma and Mylan over the right to manufacture generic Oracea. A judge has declared that Mylan infringes 1 of the patents that protects Oracea from generic copies. Some History …
February 10th, 2011, by David Pascoe | neurogenic rosacea, patents
The recently published paper that called for the creation of Neurogenic Rosacea subtype contained an interesting disclosure.
We are told that one of the paper’s authors, Professor Martin Steinhoff MD PhD , holds a related patent and research grant from Galderma.
Related Rosacea Grant
Dr. Steinhoff, along with Dr. Feramisco, received a $25,000 grant in 2010 from the National Rosacea Society.
Perhaps this below is the grant …
January 14th, 2011, by David Pascoe | acne treatments, aczone, patents, topicals
Trolling patent applications is pretty turgid work. Mostly patents seem to be intellectuals marking out their claims in the hope that future products might result from their discoveries. This patent application starts badly with firstly spelling Rosacea incorrectly as Rosascea. …
